NICE, France--(BUSINESS WIRE)--Iris Pharma, a world leader CRO specialized in ophthalmology, and OPIA Technologies, a company developping innovative medical devices for ophthalmology, announced today they have entered into a long-term licence agreement for the development of EYEPRIM®, OPIA’s main device platform, in animal studies. As part of the agreement, Iris Pharma will obtain the exclusive licence for the use of EYEPRIM® device to perform ocular surface biopsies of the living eye in its preclinical research activities.
